Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Ra Pharmaceuticals

DB:P61
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
P61
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
P61 Share Price and Events
7 Day Returns
2.3%
DB:P61
5.1%
DE Biotechs
-2.7%
DE Market
1 Year Returns
113.8%
DB:P61
-10.6%
DE Biotechs
-20.4%
DE Market
P61 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ra Pharmaceuticals (P61) 2.3% 4.3% 4.8% 113.8% 127.9% -
DE Biotechs 5.1% -5.4% -22.4% -10.6% 14.8% -8.8%
DE Market -2.7% -18.4% -26.7% -20.4% -25.9% -30.4%
1 Year Return vs Industry and Market
  • P61 outperformed the Biotechs industry which returned -10.6% over the past year.
  • P61 outperformed the Market in Germany which returned -20.4% over the past year.
Price Volatility
P61
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Ra Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ra Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ra Pharmaceuticals.

DB:P61 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:P61
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.196 (1 + (1- 21%) (0.22%))
1.132
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.132 * 5.44%)
5.77%

Discounted Cash Flow Calculation for DB:P61 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ra Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:P61 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.77%)
2020 -109.80 Analyst x2 -103.81
2021 -137.75 Analyst x2 -123.13
2022 -141.05 Analyst x2 -119.20
2023 -71.20 Analyst x1 -56.89
2024 27.10 Analyst x1 20.47
2025 38.43 Est @ 41.79% 27.44
2026 49.62 Est @ 29.14% 33.51
2027 59.69 Est @ 20.28% 38.10
2028 68.09 Est @ 14.08% 41.10
2029 74.72 Est @ 9.74% 42.64
Present value of next 10 years cash flows $-199.00
DB:P61 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $74.72 × (1 + -0.39%) ÷ (5.77% – -0.39%)
$1,208.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,208.20 ÷ (1 + 5.77%)10
$689.45
DB:P61 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-199.00 + $689.45
$490.45
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $490.45 / 47.33
$10.36
DB:P61 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:P61 represents 0.91269x of NasdaqGM:RARX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.91269x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 10.36 x 0.91269
€9.46
Value per share (EUR) From above. €9.46
Current discount Discount to share price of €43.80
= -1 x (€43.80 - €9.46) / €9.46
-363.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Ra Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ra Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ra Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:P61 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.31
NasdaqGM:RARX Share Price ** NasdaqGM (2020-04-01) in USD $47.99
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 39.37x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ra Pharmaceuticals.

DB:P61 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RARX Share Price ÷ EPS (both in USD)

= 47.99 ÷ -2.31

-20.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ra Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Ra Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ra Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:P61 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
23.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.58x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ra Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ra Pharmaceuticals's assets?
Raw Data
DB:P61 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.55
NasdaqGM:RARX Share Price * NasdaqGM (2020-04-01) in USD $47.99
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.46x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:P61 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RARX Share Price ÷ Book Value per Share (both in USD)

= 47.99 ÷ 5.55

8.65x

* Primary Listing of Ra Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ra Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ra Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ra Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ra Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ra Pharmaceuticals expected to grow at an attractive rate?
  • Ra Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Ra Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Ra Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:P61 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:P61 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 23.4%
DB:P61 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 58.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 56.8%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:P61 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:P61 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 506 28 157 3
2023-12-31 258 -70 -39 3
2022-12-31 59 -140 -178 3
2021-12-31 2 -137 -164 4
2020-12-31 9 -104 -130 7
2020-04-03
DB:P61 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 3 -87 -103
2019-09-30 6 -71 -82
2019-06-30 3 -62 -74
2019-03-31 3 -57 -67
2018-12-31 3 -55 -65
2018-09-30 -57 -64
2018-06-30 -55 -63
2018-03-31 -50 -60
2017-12-31 -47 -54
2017-09-30 0 -42 -50
2017-06-30 0 -37 -43
2017-03-31 3 -28 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ra Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Ra Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:P61 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Ra Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:P61 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.68 4.16 1.19 2.00
2023-12-31 -1.34 -1.34 -1.34 1.00
2022-12-31 -3.15 -2.66 -3.96 3.00
2021-12-31 -3.21 -3.12 -3.36 3.00
2020-12-31 -2.79 -2.76 -2.83 2.00
2020-04-03
DB:P61 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.31
2019-09-30 -2.00
2019-06-30 -1.95
2019-03-31 -1.91
2018-12-31 -2.06
2018-09-30 -2.23
2018-06-30 -2.39
2018-03-31 -2.51
2017-12-31 -2.41
2017-09-30 -2.43
2017-06-30 -2.84
2017-03-31 -3.65

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ra Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Ra Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ra Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ra Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ra Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ra Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ra Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ra Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ra Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ra Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:P61 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3.00 -102.69 27.34 82.64
2019-09-30 5.50 -82.11 19.51 71.80
2019-06-30 2.50 -73.64 17.05 61.93
2019-03-31 2.50 -67.48 15.93 56.32
2018-12-31 2.50 -64.94 14.44 54.45
2018-09-30 -63.89 13.31 51.74
2018-06-30 -62.66 12.09 51.49
2018-03-31 -59.58 10.62 49.65
2017-12-31 -54.44 9.78 45.25
2017-09-30 0.00 -50.19 8.71 41.99
2017-06-30 0.00 -43.03 7.47 35.94
2017-03-31 3.04 -35.17 6.20 31.98
2016-12-31 4.93 -28.86 5.02 27.93
2016-09-30 5.75 -22.54 4.10 23.17
2016-06-30 6.85 -16.68 3.60 20.11
2016-03-31 4.89 -14.60 3.02 16.89
2015-12-31 4.09 -12.27 2.23 15.22
2014-12-31 4.83 -5.48 1.92 10.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ra Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ra Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ra Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ra Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ra Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ra Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ra Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ra Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ra Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ra Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Ra Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ra Pharmaceuticals Company Filings, last reported 3 months ago.

DB:P61 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 262.11 0.00 264.99
2019-09-30 293.76 0.00 292.60
2019-06-30 173.69 0.00 173.60
2019-03-31 191.25 0.00 191.65
2018-12-31 207.12 0.00 209.82
2018-09-30 80.46 0.00 81.06
2018-06-30 94.92 0.00 95.06
2018-03-31 108.68 0.00 109.12
2017-12-31 69.18 0.00 70.38
2017-09-30 82.58 0.00 84.09
2017-06-30 96.18 0.00 96.61
2017-03-31 106.92 0.00 105.37
2016-12-31 117.22 0.00 117.81
2016-09-30 31.94 0.00 31.20
2016-06-30 39.74 0.00 40.25
2016-03-31 16.48 0.00 19.39
2015-12-31 16.48 0.00 19.39
2014-12-31 3.27 0.00 4.04
  • Ra Pharmaceuticals has no debt.
  • Ra Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ra Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Ra Pharmaceuticals has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 36.4% each year.
X
Financial health checks
We assess Ra Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ra Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ra Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ra Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Ra Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ra Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ra Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:P61 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 320 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:P61 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ra Pharmaceuticals has not reported any payouts.
  • Unable to verify if Ra Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ra Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ra Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Ra Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Ra Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ra Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ra Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ra Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Doug Treco
COMPENSATION $1,978,650
AGE 61
TENURE AS CEO 11.8 years
CEO Bio

Dr. Douglas A. Treco, also known as Doug, Ph.D. co-founded Ra Pharmaceuticals, Inc., and has been its President also Chief Executive Officer since June 2008. He is Entrepreneur-in-Residence at Lightstone Ventures. Dr. Treco also serves as a Visiting Scientist in the Center for Computational and Integrative Biology at Massachusetts General Hospital. He is a Lecturer in Genetics at Harvard Medical School. He co-founded Transkaryotic Therapies, Inc. in 1988 and served as its Senior Vice President of Research and Development since February 1997, with responsibility for all activities relating to research, development and manufacture of biologicals. Dr. Treco was an Entrepreneur-in-Residence at Morgenthaler since 2008. He was part of the Life Sciences team and joined in early 2008. Dr. Treco served as the Senior Vice President of Research at Shire Human Genetic Therapies Inc. until May 14, 2003. Dr. Treco has been a Director of Ra Pharmaceuticals, Inc., since June 2008. Dr. Treco served as a Director of Xcellerex, Inc. He has authored numerous peer-reviewed publications and holds 35 United States and European patents in the areas of protein production, gene mapping and gene therapy. Dr. Treco completed his post-doctoral training at Salk Institute for Biological Studies and Massachusetts General Hospital. He holds a B.S. in Biology and Chemistry from the University of Delaware and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York, Stony Brook.

CEO Compensation
  • Doug's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Doug's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ra Pharmaceuticals management team in years:

2.9
Average Tenure
46
Average Age
  • The tenure for the Ra Pharmaceuticals management team is about average.
Management Team

Doug Treco

TITLE
Co-Founder
COMPENSATION
$2M
AGE
61
TENURE
11.8 yrs

David Lubner

TITLE
Executive VP
COMPENSATION
$1M
AGE
55
TENURE
4.3 yrs

Ramin Farzaneh-Far

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
42
TENURE
3.8 yrs

Alonso Ricardo

TITLE
Chief Technology & Innovation Officer and Head of Research
AGE
41
TENURE
1.1 yrs

Simon Read

TITLE
Chief Scientific Officer
COMPENSATION
$842K
AGE
48
TENURE
4 yrs

John King

TITLE
Chief Commercial Officer
AGE
44
TENURE
2 yrs

Peter DiRoma

TITLE
Senior Vice President of Regulatory
TENURE
1.4 yrs

Joe Shulman

TITLE
Senior Vice President of Technical Operations
TENURE
0.8 yrs

Kerry Black

TITLE
Vice President of Operations
Board of Directors Tenure

Average tenure and age of the Ra Pharmaceuticals board of directors in years:

4.1
Average Tenure
51
Average Age
  • The tenure for the Ra Pharmaceuticals board of directors is about average.
Board of Directors

Ed Mathers

TITLE
Independent Chairman of the Board
COMPENSATION
$165K
AGE
59
TENURE
10.2 yrs

Doug Treco

TITLE
Co-Founder
COMPENSATION
$2M
AGE
61
TENURE
11.8 yrs

Jack Szostak

TITLE
Chairman of Scientific Advisory Board

Raj Shah

TITLE
Independent Director
COMPENSATION
$145K
AGE
42
TENURE
4.8 yrs

Tim Pearson

TITLE
Independent Director
COMPENSATION
$153K
AGE
51
TENURE
3.9 yrs

Anthony Forster

TITLE
Member of Scientific Advisory Board

Robert Heft

TITLE
Independent Director
COMPENSATION
$138K
AGE
64
TENURE
4.1 yrs

Aoife Brennan

TITLE
Independent Director
COMPENSATION
$290K
AGE
43
TENURE
1.6 yrs

Bo Cumbo

TITLE
Independent Director
COMPENSATION
$228K
AGE
48
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Ra Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ra Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company’s pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement cardiovascular targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Details
Name: Ra Pharmaceuticals, Inc.
P61
Exchange: DB
Founded: 2008
$2,088,235,322
47,328,875
Website: http://rapharma.com
Address: Ra Pharmaceuticals, Inc.
87 Cambridge Park Drive,
Cambridge,
Massachusetts, 02140,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RARX Common Stock Nasdaq Global Market US USD 26. Oct 2016
DB P61 Common Stock Deutsche Boerse AG DE EUR 26. Oct 2016
Number of employees
Current staff
Staff numbers
89
Ra Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 01:46
End of day share price update: 2020/04/01 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.